EI
HRTX icon

EAM Investors’s Heron Therapeutics HRTX Stock Holding History

EAM Investors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-349,000
Closed -$768K – 289
2025
Q1 		$768K Buy
+349,000
New +$677K 0.13% 185
2024
Q3 		– Sell
-274,076
Closed -$959K – 284
2024
Q2 		$959K Sell
274,076
-434
-0.2% -$1.33K 0.16% 167
2024
Q1 		$760K Buy
+274,510
New +$690K 0.12% 209
2018
Q4 		– Sell
-85,542
Closed -$2.71M – 278
2018
Q3 		$2.71M Sell
85,542
-9,989
-10% -$372K 0.4% 124
2018
Q2 		$3.71M Sell
95,531
-84,380
-47% -$2.69M 0.59% 40
2018
Q1 		$4.97M Buy
+179,911
New +$4.08M 0.83% 3
2016
Q3 		– Sell
-33,332
Closed -$602K – 325
2016
Q2 		$602K Sell
33,332
-1,923
-5% -$37.5K 0.09% 290
2016
Q1 		$669K Sell
35,255
-5,527
-14% -$109K 0.1% 291
2015
Q4 		$1.09M Sell
40,782
-918
-2% -$24.5K 0.14% 260
2015
Q3 		$1.02M Sell
41,700
-9,540
-19% -$318K 0.16% 259
2015
Q2 		$1.6M Sell
51,240
-179,021
-78% -$3.37M 0.19% 217
2015
Q1 		$3.35M Buy
+230,261
New +$2.6M 0.39% 110

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

EAM Investors's HRTX Position: Q2 2025 in Review

EAM Investors sold out of Heron Therapeutics (HRTX) in Q2 2025, closing a stake of 349,000 shares — an estimated $768K sold.

EAM Investors first reported a position in HRTX in Q1 2015 and held it in 12 quarters. The position peaked at $4.97M in Q1 2018. 171 funds tracked by Wall St. Rank hold HRTX as of Q2 2025.

  • EAM Investors reported no remaining Heron Therapeutics position as of Q2 2025 after selling out during the quarter.
  • EAM Investors sold 349,000 Heron Therapeutics shares in Q2 2025, an estimated $768K.
  • EAM Investors first reported a position in Heron Therapeutics in Q1 2015 and held it in 12 quarters.
  • EAM Investors's Heron Therapeutics position peaked at $4.97M in Q1 2018.
  • 171 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2025.

Based on EAM Investors's 13F filing for Q2 2025, filed 12 Aug 2025.